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The public health threat emanating from the emergence and spread of multidrug-resistant bacteria is well 
known. Each year the World Health Organization (WHO) SAVE LIVES: Clean Your Hands campaign promotes 
a different theme; the call to action in this year’s annual ‘Global Hand Hygiene Day’ on May 7th, 2017, is 
‘Fight antibiotic resistance – it’s in your hands’.1 Good hand hygiene is widely acknowledged as the single 
most important measure to prevent infections in hospital. However, it would be naive to believe that hand 
hygiene alone will solve the problems posed by multidrug-resistant Gram-negative bacteria (MDR-GNB). 
Several papers recently published in this Journal have identified that previous antibiotic exposure is an 
important independent risk factor for colonization or infection with MDR-GNB.2 ; 3 We already know that 
antibiotic stewardship has been a key component in the control of Clostridium difficile infection (CDI); 
Dingle et al. recently reported that restricting fluoroquinolone prescribing appears to have been the most 
important factor in the decline in CDI in England. 4 It is therefore timely that the WHO call to action on 
antibiotic resistance has coincided with publication of an updated Cochrane review on antibiotic 
stewardship.5 
At first glance it is encouraging that the Cochrane review concluded that interventions are effective in 
improving antibiotic stewardship.5 Key conclusions were that in 29 randomized studies, including 23,394 
inpatients, 58% of hospital inpatients in the intervention groups received treatment in line with prescribing 
guidelines, compared with 43% of the patients in the standard practice groups. Likewise, they reported 
that interventions shortened the duration of antibiotic use from 11 to nine days per patient, and probably 
reduced hospital stay from an average of 13 to 12 days per patient. Importantly, they found no evidence 
that reducing antibiotic use led to an increase in harm to patients. The latter point is important, and should 
provide support to antimicrobial management teams who may have a hard task in convincing clinicians and 
hospital managers that judicious antibiotic use is a safe strategy. However, the impact of stewardship 
interventions on antibiotic use, even in these trials that were by definition performed by motivated teams 
with adequate resources, is somewhat underwhelming. After the interventions, more than 40% of patients 
were still receiving treatment outside prescribing guidelines, and although a reduction of two days in the 
duration of antibiotic use may sound encouraging, a mean duration of therapy of nine days post 
intervention still sounds too long. 
Perhaps not surprisingly, therefore, there is limited evidence that the focus on antibiotic stewardship in 
recent years has had a significant impact on antibiotic prescribing globally. In Europe, ESAC-Net 
surveillance data for overall antibiotic consumption within the EU during 2010–2014 showed an increasing 
trend, whereas large inter-country variation in antibiotic consumption remained. In the present era of 
extensively or pan-drug-resistant carbapenemase-producing Gram-negative bacteria, it is notable that 
mean consumption of carbapenems in hospitals also increased; the increase was particularly pronounced 
in six rather diverse countries (Bulgaria, Denmark, Hungary, Ireland, the Netherlands, and Norway).6 Some 
encouraging data have recently emerged in England, where the English Surveillance Programme for 
Antimicrobial Utilisation and Resistance (ESPAUR) reported that in 2015 antibiotic use decreased 
substantially across the whole healthcare system for the first time; however, the smallest decrease was 
seen among hospital inpatients. Moreover, although the rate of increase in carbapenem use has slowed, 
between 2010 and 2015 carbapenem consumption in hospitals increased from 7.5 to 10.4 defined daily 
doses per 1000 admissions. This increase has been out of proportion to any rise in the number of infections 
caused by multidrug-resistant bacteria.7 
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Why is it that research into antibiotic stewardship does not yet seem to be translating into a measurable 
reduction in antibiotic use in hospitals? There are several possible reasons. First, findings of research 
studies many of which are performed in single centres may not be generalizable; the variation in antibiotic 
prescribing habits between countries may tell us that there is no ‘one size fits all’ approach to antibiotic 
stewardship. Sustainability of interventions is another important consideration. Studies have often been 
performed over a very short timeframe (usually a few months), and have not addressed the issue of 
maintaining a programme in the longer term against a background of rapid staff turnover (especially of 
junior doctors who are key antibiotic prescribers). There is also poor understanding of the behaviours 
around antibiotic prescribing.8 We speculate that the divergence between the rises in carbapenem use and 
the number of infections that require an antibiotic of last resort indicate a risk aversion that is not rational. 
Another consideration that has been little studied is whether the move towards healthcare becoming a 
true 24/7 industry could have impeded antibiotic stewardship, because there is less continuity in staff care 
for patients; anecdotally the authors have observed this in intensive care units. Possibly laboratory tests 
are not being used as effectively as they could be to facilitate antibiotic stewardship. Whereas the current 
generation of rapid molecular tests for bacterial infections appears to have limited value in supporting 
antibiotic stewardship, it is not clear that we are using the tests that are already at our disposal – e.g. 
blood cultures, matrix-assisted laser desorption–ionization time-of-flight (MALDI-TOF) mass spectrometry, 
and biomarkers such as procalcitonin – as effectively as we might. Finally, consideration needs to be given 
to the finances of antibiotic stewardship. Most antibiotics are relatively inexpensive, meaning that 
investment in stewardship is unlikely to be paid back by reduced antibiotic prescribing costs alone. This 
point has also been made by Ryan et al., who reported that the savings in variable costs arising from 
effective infection prevention and control interventions are rather modest. 9 
We have just been awarded funding to undertake a pilot study using a mixed methodology approach to 
investigate antibiotic prescribing behaviours. We aim to identify the critical points in the antibiotic 
prescribing pathway (from the initial prescription through the reviews of therapy to the decision to 
discontinue therapy) for hospital inpatients where stewardship interventions are most likely to be 
successful. We will investigate the extent to which antibiotic prescribing decisions are driven by matters 
such as lack of knowledge, experience or empowerment of prescribers, organizational factors, lack of 
optimal access to or use of laboratory tests, or factors relating to the built environment. Our aim is to 
identify tangible points where stewardship interventions can be tested in subsequent randomized 
controlled trials. 
1. E. Tartari, D. Pires, D. Pittet Clean Your Hands 5th May 2017: ‘Fight antibiotic resistance – it’s in your hands’ J Hosp Infect, 95 (2017), pp. 
333–334. 
2. Karaaslan, A. Soysal, G. Altinkanat Gelmez, E. Kepenekli Kadayifci, G. Söyletir, M. Bakir Molecular characterization and risk factors for 
carbapenem-resistant Gram-negative bacilli colonization in children: emergence of NDM-producing Acinetobacter baumannii in a 
newborn intensive care unit in Turkey J Hosp Infect, 92 (2016), pp. 67–72. 
3. K. Poole, R. George, V. Decraene, et al. Active case finding for carbapenemase-producing Enterobacteriaceae in a in a teaching hospital: 
prevalence and risk factors for colonization J Hosp Infect, 94 (2016), pp. 125–129. 
4. K.E. Dingle, X. Didelot, T.P. Quan, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study 
Lancet Infect Dis (2017 Jan 24) [Epub ahead of print]. 
5. P. Davey, C.A. Marwick, C.L. Scott, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients Cochrane 
Database Syst Rev, 2 (2017), p. CD003543. 
6. European Centre for Disease Prevention and Control. Summary of the latest data on antibiotic consumption in the European Union ESAC-
Net surveillance data (November 2015) Available at: http://ecdc.europa.eu/en/eaad/antibiotics-news/Documents/antimicrobial-
consumption-ESAC-Net-summary-2015.pdf [last accessed February 2017]. 
7. Public Health England.English surveillance programme for antimicrobial utilisation and resistance (ESPAUR). PHE, London (2016). 
8. Public Health England. Behaviour change and antibiotic prescribing in healthcare settings. Literature review and behavioural analysis PHE, 
London (2015). 
9. P. Ryan, M. Skally, F. Duffy, et al. Evaluation of fixed and variable hospital costs due to Clostridium difficile infection: institutional 
incentives and directions for future research J Hosp Infect, 95 (2017), pp. 415–420. 
